Toronto, Ontario - Cyclica Inc. is pleased to announce the appointment of Dr. Mostafa Analoui, Ph.D. to its Board of Directors (BoD).
Dr. Analoui brings to Cyclica deep expertise in the pharmaceutical industry, venture capital, and investment. Currently, he is the Executive Director of UConn Ventures at the University of Connecticut. Prior to that Dr. Analoui served as Head of Healthcare and Life Science at The Livingston Securities. He also served as the Senior Director and the Groton/New London Site Head for Global Clinical Technology of Pfizer Inc. Global Research and Development from 2001 to February 2008, where he led the platform technology mission for the clinical development and commercial division in areas including computational medicine. He is also an Adjunct Professor Biomedical Engineering and Entrepreneurship at University of Connecticut, Brown University and Northeastern University. He has been a member of the Board of Directors of Calando Pharmaceuticals, Inc. (known as Insert Therapeutics, Inc.), BPT Pharma, BEACON (Biomedical Engineering Alliance and CONsortium), and NanoBusiness Alliance. Providing industry leadership in the biomedical and technology fields, Dr. Analoui is actively involved in investment, management, and scientific/business development of nanotechnology, drug discovery/development, diagnostic imaging, and global strategies. Dr. Analoui has authored over 130 publications, including journal articles, book chapters, and technical reports. He holds two patents in quantitative and clinical imaging. He has received his Ph.D. from Purdue University, followed by Post-Doctoral Fellowship at IBM TJ Watson Research Center in NY.
Naheed Kurji, Cyclica’s President and CEO, is excited for Dr. Analoui’s addition to the BoD and had this to say, “Mostafa is one of those unique people who brings to Cyclica expertise across multiple domains within the pharmaceutical industry, as well as a unique ability to help think deep on core strategic issues. We are very lucky to have someone of his skillset, who is widely lauded in the space by his peer group, commit to helping guide this company forward”.
Mostafa had this to say about his appointment, “I am thrilled to join Cyclica’s talented BoD, and to help support a strong management team to build the company into a true success story. I believe that their unique computational approach solves many pain points in the pharmaceutical industry, and with a focused approach will be adopted by its players to ultimately help create safer and more effective medicines at a lower cost.”